Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 64,600
+300 (0.47%)
At close: Aug 28, 2026
Hanall Biopharma Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Hanall Biopharma stock has a consensus rating of "Strong Buy" and an average price target of ₩93,667. The average 1-year stock price forecast is 44.99% higher than the current stock price, while the lowest is ₩70,000 (+8.36%) and the highest is ₩130,000 (+101.24%).
Price Target: ₩93,667 (+44.99%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hanall Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 6 | 6 |
Financial Forecast
Revenue This Year
169.35B
from 155.18B
Increased by 9.13%
Revenue Next Year
193.77B
from 169.35B
Increased by 14.42%
EPS This Year
-346.40
from -109.00
EPS Next Year
111.45
from -346.40
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.